|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenues, net | |||||
| Product revenue, net | |||||
| License and other revenue | |||||
| Total revenues, net | |||||
| Operating expenses: | |||||
| Cost of product sales | |||||
| Research and development | |||||
| Acquired in-process research and development | |||||
| General and administrative | |||||
| Goodwill impairment | |||||
| Amortization expense | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Other (expense) income: | |||||
| Change in fair value of derivative liability | |||||
| Interest income, net | |||||
| Other expense, net | |||||
| Excess of initial warrant fair value over private placement proceeds | |||||
| Change in fair value of warrant liability | |||||
| Private placement transaction costs | |||||
| Total other (expense) income, net | |||||
| Loss before income taxes | |||||
| Income tax expense | |||||
| Net loss | |||||
| Other comprehensive income: | |||||
| Unrealized income on investments, net | |||||
| Comprehensive loss | |||||
| Net loss per share of common stock - basic (in dollars per share) | |||||
| Total net loss per share of common stock - basic (in dollars per share) | |||||
| Net loss per share of common stock - diluted (in dollars per share) | |||||
| Total net loss per share of common stock - diluted (in dollars per share) | |||||
| Weighted average common shares outstanding - basic (in shares) | |||||
| Total weighted average common shares outstanding - basic (in shares) | |||||
| Weighted average common shares outstanding - diluted (in shares) | |||||
| Total weighted average common shares outstanding - diluted (in shares) | |||||
Loading...